PROTALIX BIOTHERAPEUTICS INCPLX
ASignal's systematic analysis rates PLX as Bullish.
Reflects the latest available analysis · analyzed Oct 15, 2026
The case on PLX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong fundamental metrics including high ROE of 31.24%
- Low debt-to-equity ratio of 0.13x indicating strong financial health
- High revenue growth of 27.10% year-over-year
- Exceptional earnings growth of 2241.10% YoY
- Positive free cash flow of $2.99M
- Current price below 20-day SMA suggesting potential undervaluation
- MACD below signal line indicating bearish momentum
- Slight negative price momentum
- Limited news coverage with only one source (Yahoo)
- No Reddit mentions indicating low retail investor interest
- RSI near neutral but not oversold, limiting immediate reversal signal
See the full verdict on PLX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes PLX
Most investors never get a second opinion, let alone several. ASignal runs PLX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.